Search results
Results from the WOW.Com Content Network
CUT&RUN sequencing, also known as cleavage under targets and release using nuclease, is a method used to analyze protein interactions with DNA.CUT&RUN sequencing combines antibody-targeted controlled cleavage by micrococcal nuclease with massively parallel DNA sequencing to identify the binding sites of DNA-associated proteins.
The majority of drugs used in cancer chemotherapy are cytostatic, many via cytotoxicity. A fundamental philosophy of medical oncology , including combination chemotherapy, is that different drugs work through different mechanisms, and that the results of using multiple drugs will be synergistic to some extent.
One of these was a stem-cell like breast cancer cell line that altered its behavior under varied environmental conditions, such as the availability of oxygen and nutrients. Degradome sequencing, followed by a multistep selection process, revealed 100 protease genes that played a role in the growth of breast cancer cells.
FLAG is a chemotherapy regimen used for relapsed and refractory acute myeloid leukemia (AML). [1] The acronym incorporates the three primary ingredients of the regimen: . Fludarabine: an antimetabolite that, while not active toward AML, increases formation of an active cytarabine metabolite, ara-CTP, in AML cells;
Li-Fraumeni syndrome is caused by a gene alteration on the gene TP53. Cancer types associated with a mutation on this gene include breast cancer, soft tissue sarcoma, osteosarcoma (bone cancer), leukemia and brain tumors. In the Cowden syndrome there is a mutation on the PTEN gene, causing potential breast, thyroid or endometrial cancer. [20]
Risk factors for tumor lysis syndrome depend on several different characteristics of the patient, the type of cancer, and the type of chemotherapy used. [14] Tumor characteristics: Tumors with a high cell turnover rate, rapid growth rate, and high tumor bulk tend to be more associated with the development of tumor lysis syndrome.
Many recent, large, well-conducted studies have shown no benefits in reducing fracture risk, cardiovascular disease, cancer prevention, or death from vitamin D supplementation,” Cutler said.
The Oncotype DX Colon Cancer Assay is a genomic test for patients with newly diagnosed stage II colon cancer, launched in January 2010 by Genomic Health.The test is a validated diagnostic assay based on an individual patient's colon tumor expression of 12 genes, which quantifies the likelihood of recurrence in stage II colon cancer following surgery.